Strand Life Sciences Partners With FOGSI To Promote Genomic Testing In Women’s Healthcare

Strand Life Sciences, a subsidiary of Reliance Industries and a leader in genomic testing and bioinformatics, has partnered with the Federation of Obstetric and Gynaecological Societies of India (FOGSI) to enhance awareness about the role of genomic testing in gynaecological care. 

In a press statement on Friday, the company informed that the campaign, titled #GenomicsForHerHealth, is set to drive education and empower healthcare professionals with the latest tools in genomic medicine.

At the heart of the initiative is a Continuing Medical Education (CME) series, launching on October 25th. This educational series will focus on topics like the genetic basis of gynecologic cancers, risk assessment techniques, and the practical integration of genetic testing into clinical practice. The aim is to provide gynaecologists with the knowledge to use advanced genetic solutions to improve patient outcomes.

Speaking about the initiative, Dr. Ramesh Hariharan, CEO of Strand Life Sciences, stated, “Gynaecologic cancers are some of the most common cancers affecting women in India. Genomic testing can significantly improve the detection, treatment, and management of these cancers. This collaboration with FOGSI is a critical step towards empowering gynaecologists to offer personalised, genetics-informed care."

FOGSI President, Dr. Jaydeep Tank, added, “We aim to elevate the standard of women’s healthcare in India. By integrating genomic testing into routine gynaecological care, we are opening new doors in preventive medicine. This initiative will help identify high-risk patients early, enable preventive strategies, and save lives.”

Healthcare professionals interested in attending the CME webinar series can register via the Strand Life Sciences website or FOGSI’s portal. Certificates of participation will be awarded to those completing the series, the press statement added.